Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 7,721 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Exploring the Modulatory Role of Sex Hormones Along the Neuromechanical Axis in Females

NCT03947684
View directory record Official record
Conditions
Role of Sex Hormones Along the Neuromechanical Axis
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Phase 1 Interventional Results available

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

NCT02594384
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
Interventions
LAM-002A, Rituximab, Atezolizumab
Drug
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
11
States / cities
Huntsville, Alabama • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 23, 2026, 10:42 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

NCT04006847
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase
Interventions
Eicosapentaenoic Acid, Tyrosine kinase inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 23, 2026, 10:42 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

NCT05298358
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
RIC alloBMT w PTCy in refractory SSc
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 23, 2026, 10:42 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera

NCT03705585
View directory record Official record
Conditions
Typhoid and/or Cholera Vaccination
Interventions
Vivotif Typhoid Oral Vaccine, Vaxchora
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Phase 3 Interventional

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

NCT01235585
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, bitopertin [RO4917838]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
25
States / cities
Carson, California • Garden Grove, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Not applicable Interventional

Metabolism of Low Carbohydrate and Ketogenic Diet

NCT05071287
View directory record Official record
Conditions
Diabetic Kidney Disease, Cognitive Function, Weight Loss, Diabetic Control, Type2 Diabetes
Interventions
mHealth + low-fat diet, mHealth + low-carb/ketogenic diet
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 23, 2026, 10:42 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

NCT02634606
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 23, 2026, 10:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 10:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Measuring Smoking Behavior in People With Schizophrenia and Bipolar Disorder

NCT00382915
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
CReSSmicro handheld topography device
Device
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Foundations for Health

NCT01304615
View directory record Official record
Conditions
Overweight, Obese
Interventions
Decrease Energy Density of the Diet, Increase Steps per Day, Consumption of Self-made Meals
Behavioral
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 23, 2026, 10:42 AM EDT
Terminated Phase 1 Interventional

Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors

NCT02168725
View directory record Official record
Conditions
Neoplasms, Advanced Solid Tumor
Interventions
briciclib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Aurora, Colorado • Buffalo, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00633750
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, TUNEL assay, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, liquid chromatography, mass spectrometry, matrix-assisted laser desorption ionization mass spectrometry, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
5
States / cities
Birmingham, Alabama • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543567
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.], MVA-BN-Filo 5*10^7 Inf. U., Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
525 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

NCT01432600
View directory record Official record
Conditions
Myeloma
Interventions
Pomalidomide, Dexamethasone, Cyclophosphamide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
San Francisco, California • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 23, 2026, 10:42 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Allogeneic Stem Cell Transplant for CLL

NCT01629511
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Richter Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Filgrastim, Gemcitabine, Methotrexate, Tacrolimus
Procedure · Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Opportunities Beyond the Narrative: An Intervention for Justice-Involved Youth

NCT04795999
View directory record Official record
Conditions
Study Will Examine the Impact of Project With
Interventions
Project With
Behavioral
Lead sponsor
WestEd
Other
Eligibility
15 Years to 19 Years
Enrollment
415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Alhambra, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 23, 2026, 10:42 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Risk Presentation Format and Frequently Asked Questions on Breast Cancer Risk Skepticism

NCT07793721
View directory record Official record
Conditions
Breast Cancer
Interventions
Risk Presentation Format, Frequently Asked Questions Exposure
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
39 Years to 74 Years · Female only
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

H1N1 Vaccine at Two Dose Levels in HIV Positive Adults

NCT00992433
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza H1N1 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

NCT00069784
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 23, 2026, 10:42 AM EDT
Terminated Not applicable Interventional

Augmenting Internet-Based Cognitive Behavioral Therapy for Major Depressive Disorder With Low-Level Light Therapy

NCT02898233
View directory record Official record
Conditions
Depression
Interventions
Deprexis, Active low-level light therapy, Sham low-level light therapy
Other · Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019

NCT04883528
View directory record Official record
Conditions
Covid19
Interventions
Sacubitril / Valsartan Oral Tablet [Entresto], Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 23, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer

NCT00934128
View directory record Official record
Conditions
Advanced Cancers
Interventions
Vapotherm, BIPAP
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 23, 2026, 10:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Activator and Type II Diabetics

NCT01782092
View directory record Official record
Conditions
Type II Diabetes
Interventions
Chiropractic Adjustment
Other
Lead sponsor
Life University
Other
Eligibility
30 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Oct 23, 2026, 10:42 AM EDT